Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 90 publications.

Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Beyhagh H, Toback S. Reactogenicity differences between adjuvanted, protein-based and messenger ribonucleic acid (mRNA)-based COVID-19 vaccines. Vaccines (Basel). 2024 Jul 19;12(7):802. doi: 10.3390/vaccines12070802

Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Miller A, Toback S. Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United States and Canada: results from a prospective observational study. Vaccines (Basel). 2024 Jan 13;12(1):83. doi: 10.3390/vaccines12010083

Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619

Toback S, Hollis K, Beyhaghi H, Ziemiecki R, Odom D, Choi JM, Layton JB, Odak S, Jackson L, Williams V, Marchese AM, Milller A, Rousculp M. Presenteeism: the reality to be discussed with COVID-19 vaccine recipients. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.

Rousculp M, Beyhaghi H, Hollis K, Ziemiecki R, Layton JB, Odak S, Jackson L, Odom D, Williams V, Choi JM, Montazeri M, Marchese AM, Toback S. Burden and impact of reactogenicity among United States and Canadian adults receiving COVID-19 vaccines: Vaccine Impact on Productivity (VIP) Study. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.

Shim A, Trone D, Reynolds M, Odom D, Sherif B, Stopatschinskaja S. Patient reported outcomes (PRO) from phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S421. doi: 10.1016/j.jval.2022.09.2093

Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.

Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939

Chirila C, Odom D, Gnanasakthy A. Patient-reported outcomes assessment scheduling in oncology: are we introducing potential bias? Presented at the 2021 DIA Virtual Annual Meeting; June 27, 2021.

Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Can C, Chassot-Agostinho A, Reynolds M, Odom D, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the phase II GEOMETRY mono-1 study. Poster presented at the ASCO 2021 Annual Meeting; June 4, 2021.

Rasouliyan L, Odom D. WORTH the weight: evaluation of weighting strategies in unanchored matching-adjusted indirect comparison. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7

Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15;229:220-9. doi: 10.1016/j.ajo.2021.03.007

Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE Study. Poster presented at the Virtual 12th European Breast Cancer Conference; October 2, 2020.

Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Jones C, Mahtani R, Hargis J. The effect of neutropenia on patient-reported functioning and Quality of Life (QOL) among palbociclib participants of the MADELINE Study. Poster presented at the 2020 ASCO Virtual Scientific Program; June 2020. [abstract] J Clin Oncol. 2020 Jun; 38(2020):1064. doi: 10.1200/JCO.2020.38.15_suppl.1064

Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos MA. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial. Eur J Haematol. 2020 May;104(5):443-58. doi: 10.1111/ejh.13379.

Todenhofer T, Fizazi K, Shore ND, Tammela T, Kuss I, Le Barre M-A, Mohammed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Poster presented at the 2020 German Cancer Congress; February 2020. [abstract] Oncol Res Treat. 2020 Feb; 43(Suppl 1):154-5. Previously presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Richardson D, Zhan L, Reynolds M, Odom D, McRoy L, Mitra D, Hargis J. Relationship between depression status and daily and weekly mood in the MADELINE study. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 11, 2019. San Antonio, TX.

Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Richardson D, Zhan L, Reynolds M, Odom D, McRoy L, Mitra D, Zelnak A, Jones C. Virtual community engagement among women receiving palbociclib for HR+/ HER2- metastatic breast cancer: data from the Madeline study. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(SE).

Hofheinz R, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types. Poster presented at the 2019 ESMO World Congress on Gastrointestinal Cancer Conference; July 2019. Barcelona, Spain.

Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.

Richardson D, Mitra D, Hollis K, Reynolds M, Odom D, Kaye JA, Zhan L, McRoy L. A prospective, observational study of mobile application-based patient-reported outcomes in advanced breast cancer: select patient-reported interim data from the MADELINE study. Poster presented at the 36th Annual Miami Breast Cancer Conference; March 2019. Miami, FL.

Odom D, Mitra D, Hollis K, Richardson D, Kaye J, McRoy L. A prospective observational study of mobile application-based Patient-Reported Outcomes (PRO) in advanced breast cancer: interim baseline data from the MADELINE study. Poster presented at the 2018 ESMO Congress; October 2018. Munich, Germany.

Odom D, Purser M, Rasouliyan L. An overview of matching adjusted indirect comparisons in single arm clinical trials with practical recommendations and potential challenges. Presented at the 2018 Joint Statistical Meetings; August 2, 2018. Vancouver, Canada.

Odom D, McLeod L, Sherif B, Nelson L, McSorley D. Longitudinal modeling approaches to assess the association between changes in 2 clinical outcome assessments. Ther Innov Regul Sci. 2018 May;52(3):306-12. doi: 10.1177/2168479017731584

La EM, Trantham L, Kurosky SK, Odom D, Aris E, Hogea C. An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability. Hum Vaccin Immunother. 2018 Feb 1;14(2):430-41. doi: 10.1080/21645515.2017.1403697

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Curr Med Res Opin. 2017 Aug;33(8):1457-66. doi: 10.1080/03007995.2017.1325730

La E, Trantham L, Kurosky S, Odom D, Aris E, Hogea C. An analysis of the heterogeneity in adult vaccination coverage in the United States: beyond the national level. Poster presented at the 20th Annual Conference on Vaccine Research; April 24, 2017. Bethesda, MD.

Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.

White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675

Odom D, Zhou X, Thomas S. Reporting of the trimmed population in propensity score analyses. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):147-8.

White MV, Silvia S, Hollis K, Goss D, Odom D, Bartsch J, Hogue SL. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the NASN 2016 48th Annual Conference; June 30, 2016. Indianapolis, IN. Previously presented at the 2016 AAAAI Annual Meeting.

Odom D, Mladsi DM, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A122.

Hogue SL, Silvia S, Hollis K, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S116. Previously presented at the 2016 ACAAI Conference.

Hogue SL, Silvia S, Hollis K, Wooddell MJ, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 ACAAI Conference; March 4, 2016. Los Angeles, CA.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.

White MV, Silvia S, Hollis K, Wooddell M, Goss D, Odom D, Cooney D, Bartsch J, Hogue S. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the 2016 AAAAI Annual Meeting; March 4, 2016. Los Angeles, CA. [abstract] J Allergy Clin Immunol. 2016; 137:AB52.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Bonthapally V, Ma E, Viviani S, Radford J, Brice P, von Tresckow B, Thomas E, Teasell J, Gnanasakthy A, Odom DM. Healthcare utilization in the AETHERA trial: phase 3 Study of brentuximab vedotin in patients at increased risk of residual hodgkin lymphoma post-ASCT. Poster presented at the 13th International Conference on Malignant Lymphoma (ICML); June 17, 2015. Lugano, Switzerland.

Bonthapally V, Ma E, Viviani S, Radford J, Brice P, von Tresckow B, Thomas E, Teasell J, Gnanasakthy A, Odom DM, Zhu Y, Lee S, Carlson P, Huebner D, Sweetenham J, Moskowitz C, Walewski J. Brentuximab vedotin in patients at increased risk of hodgkin lymphoma progression post autologous stem cell transplant: evaluation of healthcare resource utilization in the AETHERA trial. Poster presented at the 20th Congress of the European Hematology Association; June 2015. Vienna, Austria.

Chang J, Ngai C, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 ASCO Annual Meeting; May 29, 2015. Chicago, IL.